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Atypical group 1 neuraminidase pH1N1-N1
bound to a group 1 inhibitor
Dear Editor,
Inﬂuenza virus is a member of the Orthomyxoviridae family
and is the causative agent of seasonal and pandemic ﬂu.
There are three types of inﬂuenza virus: A, B and C. Inﬂu-
enza A viruses possess the greatest host-range and reas-
sortment ability and all known inﬂuenza pandemics have
been caused by type A. Inﬂuenza A viruses contain 8 neg-
ative-strand RNA segments, encoding 14 proteins, including
3 major surface proteins, hemagglutinin (HA), neu-
raminidase (NA) and the M2 proton channel. Due to their
accessibility on the surface of the virus, HA, NA and M2 have
been the primary targets for the design of anti-inﬂuenza
therapeutics (Du et al., 2012).
NA is a retaining sialidase that catalyzes hydrolysis of the
ketosidic bond of terminally linked sialic acid residues,
thereby functioning as the inﬂuenza receptor-destroying
element. As a surface enzyme that can be targeted by
transition state analogues, NA is currently the most suc-
cessful anti-inﬂuenza drug target with several successful
drugs commercially available or under clinical trials (von
Itzstein, 2007; Moscona, 2008; Vavricka et al., 2013).
There are currently 9 known subtypes of functional inﬂu-
enza A NA based upon antigenicity. These 9 subtypes can be
categorized into two phylogenetic groups with N1, N4, N5 and
N8 in group 1, and N2, N3, N6, N7 and N9 in group 2 (Wu
et al., 2014). Based on earlier crystal structures of N2 (Col-
man et al., 1983) and N9 (Webster et al., 1987), structure-
based inhibitors, like zanamivirs and oseltamivir, were
developed. In 2006, the ﬁrst group 1 NA crystal structures of
N1, N4 and N8 were solved and they all contained an addi-
tional cavity adjacent to the active site, the 150-cavity, which
is formed by an open conformation of the 150-loop (residues
147–151) (Russell et al., 2006). Since then, novel inhibitors
targeting this extra cavity have been pursued, with 3-(p-tolyl)
allyl-Neu5Ac2en (Rudrawar et al., 2010) as a good example
of such an inhibitor. This compound demonstrated speciﬁcity
for inhibition of group 1 over group 2 NAs (N1 NA: Ki 2 µmol/L;
N2 NA: Ki 220 µmol/L) and selective inhibition of the growth of
N1-containing viruses compared with an N2-containing virus
in plaque reduction assays (Rudrawar et al., 2010).
Previously we reported that the 2009 pandemic H1N1
inﬂuenza virus (pH1N1) NA (09N1) does not have a
150-cavity and therefore it was unclear whether or not group
1 speciﬁc inhibitors which access the 150-cavity could be
effective against it (Li et al., 2010). We proposed that the
I149V mutant may play a role in the unique 150-loop prop-
erties of 09N1. Meanwhile, it has been reported that group 1
speciﬁc inhibitor 3-(p-tolyl)allyl-Neu5Ac2en does indeed
work against 09N1 (Rudrawar et al., 2010). Therefore in this
study we prepared 09N1 with and without the I149V sub-
stitution and soaked 3-(p-tolyl)allyl-Neu5Ac2en into both
forms. We found that 3-(p-tolyl)allyl-Neu5Ac2en bound both
proteins in a similar conformation, but distinct from the
canonical group 1 members N8 and N5. In contrast, 3-(p-
tolyl)allyl-Neu5Ac2en could not be soaked into the group 2
member, N2, but rather the inhibitor was found to bind the
second binding site (Kobasa et al., 1997) of group 2 member,
N3, further conﬁrming the inability of group 2 NA to bind 3-(p-
tolyl)allyl-Neu5Ac2en.
NA proteins were produced using a baculovirus expres-
sion system as described previously (Li et al., 2010). 09N1,
N2, N3 and N5 are from A/California/04/2009 (H1N1), A/RI/5
+/1957(H2N2), A/Swine/Missouri/2124514/2006 (H2N3) and
A/duck/Alberta/60/1976 (H12N5), respectively. 09N1-I149V
mutant was generated by using primer F: 5′-CATTCCA
ATGGAACCGTTAAAGACAGGAGC-3′ and primer R: 5′-GC
TCCTGTCTTTAACGGTTCCATTGGAATG-3′. 3-(p-tolyl)allyl-
Neu5Ac2en was produced according to the reported
methods.
The protein crystals were grown according to our previous
reports (Li et al., 2010). 09N1-I149V crystals were obtained
in exactly the same condition as 09N1 (Li et al., 2010). All
crystals were ﬁrst incubated in mother liquor containing
5–20 mmol/L inhibitor for 2–3 h and then ﬂash-cooled at
100 K. Diffraction data were collected at KEK beamline BL1A
or SSRF beamline BL17U. The data were processed and
scaled by using the HKL-2000 software program. Data col-
lection and processing statistics are summarized in Table S1.
All the NA complex structures with 3-(p-tolyl)allyl-Neu5Ac2en
were solved by molecular replacement using Phaser from the
CCP4 program suite.
The structure of 09N1-I149V mutant still displayed a
closed 150-loop as did that of 09N1 (Fig. 1A and 1B,
respectively). Earlier work showed that a 09N1 with the drug
resistant I223R substitution does contain an opened
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150-loop, and consequently the 150-cavity (van der Vries
et al., 2012). When scrutinized, in the 09N1-I223R structure,
phosphate is also present and a salt bridge is formed
between the phosphate ion and the K150 amino group,
which maintains the open 150-loop (van der Vries et al.,
2012) (Fig. 1C). The structures of 09N1 and its mutant 09N1-
I149V ﬁt well with each other with a RMSD of 0.097 Å
(Fig. 1D).
Previous molecular dynamics simulations have con-
cluded that the 150-loop of 09N1 should prefer the open
conformation and that the I149V mutant should prefer the
closed conformation (Amaro et al., 2011). Yet, we can
directly observe in high resolution crystal structures that both
09N1 and the I149V mutant prefer a closed 150-loop con-
formation, relative to other group 1 NAs, speciﬁcally N5 and
N8 (Figs. 2 and S1).
The complex structures of 3-(p-tolyl)allyl-Neu5Ac2en with
09N1 and 09N1-I149V were solved at 1.7 Å and 2.0 Å,
respectively. In both complex structures, the atypical group 1
150-loops are forced half-open into a similar disordered
conformation with electron density lacking for residues T148
and I149 (Fig. 2A–D). This explains why the atypical group 1
09N1 can still be inhibited by 150-cavity targeting inhibitors,
but with lower efﬁcacy (Rudrawar et al., 2010), as the
150-loop is ﬂexible enough to accommodate the inhibitors.
The complex structure of N5 with 3-(p-tolyl)allyl-Neu5A-
c2en was solved at 1.8 Å and the complex structure clearly
showed the characteristics observed earlier for the N8
complex (Rudrawar et al., 2010) (Fig. 2E–H). Soaking of
group 2 NAs, N2 and N3, with 3-(p-tolyl)allyl-Neu5Ac2en did
not result in typical NA inhibitor complex structures, with the
inhibitor bound in the active site. Rather, for N3, 3-(p-tolyl)
allyl-Neu5Ac2en was bound to the second sialic acid binding
site between two adjacent NA molecules (Fig. 2I and 2J).
Figure 1. Comparison of the enzymatic active site of 09N1
and its mutant 09N1-I149V. (A and B) Surface representation
of the active site of 09N1-I149V (orange) and 09N1 (green),
respectively; (C) Surface representation of 09N1-I223R active
site (white), where a phosphate ion (orange) interacts with K150
(blue) to open up the 150-cavity; (D) Alignment of 09N1 and
09N1-I149V in cartoon representations. 09N1 is in green and
09N1-I149V is in orange; The RMSD between the two structures
is only 0.097 Å.
Figure 2. 3-(p-Tolyl)allyl-Neu5Ac2en is a group 1 speci-
ﬁc inhibitor. The left column shows the molecular surface
of 09N1 (A, green), 09N1-I149V (C, orange), N8 (E, blue),
N5 (G, magenta) and N3 (I, cyan), all in complex with 3-(p-
tolyl)allyl-Neu5Ac2en, which is shown in stick representa-
tion. The right column is the corresponding sigma A
weighted electron density map contoured at 1 sigma for
the 150-loop in cartoon representation (B, 09N1; D, 09N1-
I149V; F, N8; H, N5 and J, N3). For the group 2 NA N3,
3-(p-tolyl)allyl-Neu5Ac2en binds to the second sialic acid
binding site instead of the active site.
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In our experiments, the inability to obtain complex struc-
tures with group 2 N2 or N3 supports the hypothesis that the
inhibitor 3-(p-tolyl)allyl-Neu5Ac2en exhibits speciﬁcity for
group 1 NA. This explains further why poorer inhibition of N2
by this group-1-targeted inhibitor was generally observed
(Rudrawar et al., 2010). From the aspect of drug-resistance,
3-(p-tolyl)allyl-Neu5Ac2en, which is based upon Neu5A-
c2en, has an advantage over other group 1 inhibitors which
are based upon the oseltamivir structure (Kerry et al., 2013).
To further the biological relevance of our data, we evalu-
ated the inhibition efﬁcacy of 3-(p-tolyl)allyl-Neu5Ac2en to
both 09 pH1N1 and 09 pH1N1-I149V viruses in cell-based
plaque reduction assay. Recombinant viruses were gener-
ated by reverse genetics using previously described methods
(Wu et al., 2013). The IC50 values were determined by using
the same titer of 09 pH1N1 and 09 pH1N1-I149V viruses.
4-MUNANA (4-methylumbelliferyl-N-acetylneuraminic acid)
was used as a ﬂuorescent NA substrate according to previ-
ously reported methods (Wu et al., 2013). As expected, the
efﬁcacy of 3-(p-tolyl)allyl-Neu5Ac2en for virus is in micro
molar range (the corresponding IC50 values for 09 pH1N1
and the I149V mutant virus were 35 µmol/L and 31 µmol/L,
respectively), which needs to be improved for a clinically-
therapeutic inhibitor. Therefore, with this work we provide
further evidence of the binding modes that are possible for
the novel class of NA inhibitor represented by 3-(p-tolyl)allyl-
Neu5Ac2en, which will contribute to further development of
this inhibitor class in the future.
In conclusion, our results indicate that 09N1 is truly an
atypical group 1 NA and possesses unique 150-loop prop-
erties, but the group 1 speciﬁc inhibitors still do work against
it. Furthermore, the novel complex structures in this study
demonstrate the inherent ﬂexibility of the group 1 150-loop,
which can adopt many distinct conformations. Therefore it is
probable that more structural diversity will be observed in
future structural studies. In addition, we also provided the
crystal-clear evidence that the novel inhibitor can bind the
group 2 member N3 in its second sialic acid binding site. The
biological signiﬁcance of this observation is worthy of further
investigation.
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